Clinical trial NCT05147233
Conditions: Inflammation Eye Pain Postoperative Cataract
Sponsor: Oculis
Start date: 2022-06-24; Completion date: 2023-07-03
Enrollment: 241 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.

Detailed description:

Arms: arm 1: 1 drop of OCS-01 (Dexamethasone ophthalmic suspension 1.5% \[15 mg/mL\]) in the study eye once daily (QD) for 14 days, beginning 1-day post-surgery in the study eye. arm 2: 1 drop of vehicle in the study eye QD for 14 days, beginning 1-day post-surgery in the study eye.
Interventions: intervention 1: OCS-01 intervention 2: Vehicle
Intervention descriptions: intervention 1: Dexamethasone ophthalmic suspension, 1.5% intervention 2: Vehicle

Protocol documents:
Prot_000.pdf: 





6<1236,6
3URWRFRO 7LWOH
$ 5DQGRPL]HG 'RXEOHPDVNHG 9HKLFOHFRQWUROOHG 6WXG\
(YDOXDWLQJ WKH (IILFDF\ DQG 6DIHW\ RI 2&6 H\HGURSV
FRPSDUHG WR 9HKLFOH LQ WKH 7UHDWPHQW RI ,QIODPPDWLRQ DQG 3DLQ
)ROORZLQJ &DWDUDFW 6XUJHU\
,1' 
3URWRFRO 1XPEHU
';
6WXG\ 'UXJV
 2&6 'H[DPHWKDVRQH 2SKWKDOPLF 6XVSHQVLRQ 
PJP/
 3ODFHER YHKLFOH IRU 2&6
6WXG\ 3KDVH

2EMHFWLYHV
7KH SULPDU\ REMHFWLYH RI WKLV VWXG\ LV WR HYDOXDWH WKH HIILFDF\
DQG VDIHW\ RI 2&6 FRPSDUHG WR SODFHER YHKLFOH LQ WKH
WUHDWPHQW RI LQIODPPDWLRQ DQG SDLQ IROORZLQJ FDWDUDFW VXUJHU\
2YHUDOO 6WXG\ 'HVLJQ
6WUXFWXUH
0XOWLFHQWHU UDQGRPL]HG GRXEOHPDVNHG SODFHER YHKLFOH
FRQWUROOHG VWXG\
'XUDWLRQ
$SSUR[LPDWHO\  GD\V
&RQWUROV
3ODFHER YHKLFOH IRU 2&6
'RVDJH'RVH 5HJLPHQ
,QVWLOODWLRQ
$SSOLFDWLRQ8VH
6XEMHFWV ZLOO EH UDQGRPL]HG WR RQH RI WKH IROORZLQJ WUHDWPHQW
JURXSV LQ D IDVKLRQ
 2&6 RQFH GDLO\ 4'
 3ODFHER YHKLFOH 4'
$OO TXDOLILHG VXEMHFWV ZLOO GRVH IRU  GD\V EHJLQQLQJ  GD\ SRVW
VXUJHU\ LQ WKH RSHUDWHG H\H 'RVH VKRXOG EH LQVWLOOHG DW
DSSUR[LPDWHO\  $0   KRXUV
6XPPDU\ RI 9LVLW
6FKHGXOH
9LVLW  
>SULRU WR VXUJHU\@ 6FUHHQLQJ EDVHOLQH
HYDOXDWLRQV LQFOXGLQJ HQGRWKHOLDO FHOO GHQVLW\
9LVLW  
V SRVWVXUJHU\@ 5HYLHZ RI
LQFOXVLRQ DQG H[FOXVLRQ FULWHULD UDQGRPL]DWLRQ DQG GRVLQJ
DQG GLVSHQVDWLRQ RI VWXG\ PHGLFDWLRQ
9LVLW  
3DLQ DVVHVVPHQWV 

9LVLW  
 ,QIODPPDWLRQ SDLQ DQG VDIHW\
DVVHVVPHQWV
9LVLW  
 ,QIODPPDWLRQ SDLQ DQG VDIHW\ DVVHVVPHQWV
2FXOLV
';
2&6
9HUVLRQ 
&RQILGHQWLDO
3DJH  RI 
























6DIHW\ $QDO\VLV
7KH SULPDU\ VDIHW\ DQDO\VHV ZLOO VXPPDUL]H 9$ ,23 DQG $(V DV GHVFULEHG EHORZ
9$ GDWD ZLOO EH VXPPDUL]HG DW HDFK YLVLW XVLQJ GLVFUHWH VXPPDULHV LQFOXGLQJ PHDQ FKDQJH
IURP EDVHOLQH LQ WKH QXPEHU RI OHWWHUV DQG WKH SURSRUWLRQ RI VXEMHFWV ZLWK ZRUVHQLQJ IURP
SUHYLRXV YLVLW RI   OLQHV XVLQJ WKH (7'56 VFDOH
,23 ZLOO EH VXPPDUL]HG DW HDFK YLVLW XVLQJ FRQWLQXRXV DQG GLVFUHWH VXPPDU\ VWDWLVWLFV
LQFOXGLQJ PHDQ FKDQJH IURP EDVHOLQH DQG WKH SURSRUWLRQ RI VWXG\ H\HV ZLWK DQ LQFUHDVH IURP
EDVHOLQH LQ ,23 RI  PP+J RU PRUH DQGWKH SURSRUWLRQ RI VWXG\ H\HV ZLWK ,23 RI  PP+J
RU PRUH
2FXODU WUHDWPHQWHPHUJHQW $(V 7($(V LQ WKH VWXG\ H\H IRU DOO WUHDWHG VXEMHFWV ZLOO EH
VXPPDUL]HG XVLQJ GLVFUHWH YDULDEOHV DW WKH VXEMHFW DQG HYHQW OHYHO E\ V\VWHP RUJDQ FODVV
62& DQG SUHIHUUHG WHUP 37 IRU HDFK WUHDWPHQW JURXS $ 7($( ZLOO EH GHILQHG DV DQ\ $(
WKDW RFFXUV DIWHU WKH WUHDWPHQW LV LQLWLDWHG $Q DGGLWLRQDO DQDO\VLV ZLOO H[DPLQH RFXODU $(V IRU
WKH QRQVWXG\ H\H 1RQRFXODU 7($(V ZLOO EH VXPPDUL]HG XVLQJ GLVFUHWH VXPPDULHV DW WKH
VXEMHFW DQG HYHQW OHYHO E\ 62& DQG 37 IRU HDFK WUHDWPHQW JURXS 7UHDWPHQW UHODWHG RFXODU
DQG QRQRFXODU 7($(V ZLOO EH VXPPDUL]HG VLPLODUO\ 2FXODU DQG QRQRFXODU 7($(V ZLOO DOVR
EH VXPPDUL]HG E\ VHYHULW\
6OLW ODPS ELRPLFURVFRS\ DQG GLODWHG LQGLUHFW RSKWKDOPRVFRS\ PHDVXUHV ZLOO EH VXPPDUL]HG
DW HDFK YLVLWLQFOXGLQJ VKLIW IURP EDVHOLQH DV DSSURSULDWH XVLQJ GLVFUHWH VXPPDU\ VWDWLVWLFV
9HUVLRQ 
'DWH 0D\  
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 










/LVW RI $EEUHYLDWLRQV
Ȗ&'
ȖF\FORGH[WULQ
$(
DGYHUVH HYHQW
%,'
WZLFH D GD\
%3+
EHQLJQ SURVWDWLF K\SHUSODVLD
&,
FRQILGHQFH LQWHUYDO
&'
F\FORGH[WULQ
&)5
&RGH RI )HGHUDO 5HJXODWLRQV
H&5)
HOHFWURQLF FDVH UHSRUW IRUP
(0$
(XURSHDQ 0HGLFLQHV $JHQF\
(7'56
(DUO\ 7UHDWPHQW RI 'LDEHWLF 5HWLQRSDWK\ 6WXG\
)$6
IXOO DQDO\VLV VHW
)'$
)RRG DQG 'UXJ $GPLQLVWUDWLRQ
*&3
*RRG &OLQLFDO 3UDFWLFH
,%
,QYHVWLJDWRU¶V %URFKXUH
,&)
LQIRUPHG FRQVHQW IRUP
,&+
,QWHUQDWLRQDO &RQIHUHQFH RQ +DUPRQLVDWLRQ
,23
LQWUDRFXODU SUHVVXUH
,5%
LQVWLWXWLRQDO UHYLHZ ERDUG
,8'
LQWUDXWHULQH GHYLFH
/2&)
ODVW REVHUYDWLRQ FDUULHG IRUZDUG
0,*6
PLQLPDOO\ LQYDVLYH JODXFRPD VXUJHU\
P725
PDPPDOLDQ WDUJHW RI UDSDP\FLQ
16$,'
QRQVWHURLGDO DQWLLQIODPPDWRU\ GUXJ
3&,2/
3RVWHULRU FKDPEHU LQWUDRFXODU OHQV
3,
3ULQFLSDO ,QYHVWLJDWRU
33
SHU SURWRFRO
37
SUHIHUUHG WHUP
4'
RQFH D GD\
6$(
VHULRXV DGYHUVH HYHQW
6$3
VWDWLVWLFDO DQDO\VLV SODQ
62&
V\VWHP RUJDQ FODVV
7($(
WUHDWPHQWHPHUJHQW DGYHUVH HYHQWV
9$
YLVXDO DFXLW\
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 








1&7 'LIOXSUHGQDWH  (\H 'URSV &RPSDUHG WR 3ODFHER IRU ,QIODPPDWLRQ
)ROORZLQJ 2FXODU 6XUJHU\
1&7 /RWHPD[  *HO &RPSDUHG WR 3ODFHER IRU ,QIODPPDWLRQ DQG 3DLQ
)ROORZLQJ &DWDUDFW 6XUJHU\

0HDVXUHV 7R (QVXUH 6DIH 3DUWLFLSDWLRQ LQ WKH 6WXG\
3ODFHERFRQWUROOHG VWXGLHV PD\ RQO\ EH HWKLFDOO\ FRQGXFWHG ZKHQ VXEMHFWV DW D FRQWUROOHG ULVN
DUH LQFOXGHG VXEMHFWV DUH IXOO\ LQIRUPHG RI DOO WKH SRWHQWLDO ULVNV VXEMHFWV DUH FDUHIXOO\
PRQLWRUHG DQG DGHTXDWH SURWRFRO VDIHW\ PHDVXUHV DUH LQ SODFH ,Q WKLV SURSRVHG WULDO D QXPEHU
RI JHQHUDO SURWHFWLYH PHDVXUHV DUH LQFRUSRUDWHG LQWR WKH VWXG\ SURWRFRO ZLWK WKH LQWHQWLRQ WR
PLQLPL]H WKH ULVN WR VXEMHFWV
7KH IROORZLQJ VSHFLILF PHDVXUHV DUH LQFOXGHG LQ WKH SURWRFRO
x
6XEMHFWV DW ORZ ULVN DUH VHOHFWHG DQG WKH\ ZLOO EH IXOO\ LQIRUPHG RI WKHLU FKDQFHV
RI UDQGRPL]DWLRQ WR WKH SODFHER JURXS GXULQJ LQIRUPHG FRQVHQW
x
6XEMHFWV DUH FDUHIXOO\ PRQLWRUHG IRU SDLQ DQG LQIODPPDWLRQ IROORZLQJ FDWDUDFW VXUJHU\
x
7KH UHVFXH DQG ZLWKGUDZDO FULWHULD PLQLPL]H VXEMHFW ULVN DQG ZLOO DOORZ SURSHU PHGLFDO
FDUH
%DVHG RQ WKH DERYH UDWLRQDOH DQG WKH PHDVXUHPHQWV IRU D VDIH PHGLFDO VXSHUYLVLRQ IRU WKH
VXEMHFWV 2FXOLV EHOLHYHV WKDW LW LV VFLHQWLILFDOO\ DQG HWKLFDOO\ DSSURSULDWH WR XVH SODFHER FRQWURO
LQ WKH VWXG\ ';

678'< 2%-(&7,9(6 $1' +<327+(6,6

6WXG\ 2EMHFWLYH
7KH SULPDU\ REMHFWLYH RI WKLV VWXG\ LV WR HYDOXDWH WKH HIILFDF\ DQG VDIHW\ RI 2&6 4'
FRPSDUHG WR SODFHER YHKLFOH LQ WKH WUHDWPHQW RI LQIODPPDWLRQ DQG SDLQ IROORZLQJ FDWDUDFW
VXUJHU\

6WXG\ +\SRWKHVLV
,W LV K\SRWKHVL]HG WKDW WKH SODQQHG 4' GRVH RI 2&6 YLD WRSLFDO RSKWKDOPLF DGPLQLVWUDWLRQ
ZLOO EH VDIH HIIHFWLYH DQG ZHOO WROHUDWHG LQ VXEMHFWV SRVWFDWDUDFW VXUJHU\

29(5$// 678'< '(6,*1
7KLV LV D PXOWLFHQWHU UDQGRPL]HG GRXEOHPDVNHG SODFHER YHKLFOHFRQWUROOHG VWXG\ GHVLJQHG
WR HYDOXDWH WKH HIILFDF\ DQG VDIHW\ RI 2&6 FRPSDUHG WR SODFHER LQ WUHDWLQJ LQIODPPDWLRQ DQG
SDLQ IROORZLQJ FDWDUDFW VXUJHU\
6XEMHFWV ZLOO EH UDQGRPL]HG  WR UHFHLYH 2&6 RU SODFHER 4' 6XEMHFWV ZLOO GRVH  GURS LQ
WKH VWXG\ H\H 4' IRU  GD\V EHJLQQLQJ  GD\ SRVWVXUJHU\ LQ WKH RSHUDWHG H\H 7KH VWXG\ ZLOO
ODVW  GD\V LQFOXGLQJ VFUHHQLQJ DQG D IROORZXS YLVLW DW 9LVLW  
IRU
HQGRWKHOLDO FHOO GHQVLW\ DVVHVVPHQW
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 










x
6WXG\ WHUPLQDWHG E\ WKH 6SRQVRU
x
2WKHU
1RWH ,Q DGGLWLRQ DQ\ VXEMHFW PD\ EH GLVFRQWLQXHG IRU DQ\ VRXQG PHGLFDO UHDVRQ
,I DW DQ\ WLPH GXULQJ WKH VWXG\ WKH ,QYHVWLJDWRU GHHPV WKDW WKH VXEMHFW¶V VDIHW\ KDV EHHQ
FRPSURPLVHG RU WKH VXEMHFW KDV EHHQ QRQFRPSOLDQW WKH VXEMHFW PD\ EH ZLWKGUDZQ IURP WKH
VWXG\
1RWLILFDWLRQ RI D VXEMHFW¶V GLVFRQWLQXDWLRQ DQG WKH UHDVRQ IRU GLVFRQWLQXDWLRQ ZLOO EH PDGH WR 2UD
DQGRU WKH 6SRQVRU DQG ZLOO EH FOHDUO\ GRFXPHQWHG RQ WKH H&5)
$Q\ VXEMHFW ZKR GLVFRQWLQXHV VWXG\ GUXJ RU ZKR LV DGPLQLVWHUHG UHVFXH WKHUDS\ ZLOO UHPDLQ
HQUROOHG LQ WKH VWXG\ DQG FRQWLQXH WR SDUWLFLSDWH LQ DOO VXEVHTXHQW YLVLWV IRU VDIHW\ DQG HIILFDF\
DVVHVVPHQWV 6XFK D VXEMHFW ZLOO EH LQFOXGHG LQ WKH VHQVLWLYLW\ DQDO\VHV EXW QRW DQDO\]HG IRU
SULPDU\ HQGSRLQW HIILFDF\ ,I D VXEMHFW GLVFRQWLQXHV SDUWLFLSDWLRQ LQ WKH VWXG\ HDUO\ HYHU\
DWWHPSW ZLOO EH PDGHWR FRPSOHWH WKH H[LW SURFHGXUHV UHTXLUHG DW WKH ILQDO VWXG\ YLVLW 9LVLW 

678'< 3$5$0(7(56

(IILFDF\ 0HDVXUHV

3ULPDU\ (IILFDF\ 0HDVXUH
+LHUDUFKLFDO 3ULPDU\ (IILFDF\ 0HDVXUHV
x
$EVHQFH RI DQWHULRU FKDPEHU FHOOV LH VFRUH RI µ¶ DW 9LVLW  

x
$EVHQFH RI SDLQ LH VFRUH RI µ¶ DW 9LVLW  


3ULPDU\ (IILFDF\ $QDO\VHV
7KH KLHUDUFKLFDO SULPDU\ HIILFDF\ DQDO\VHV DUH DV IROORZV
x
'LIIHUHQFH EHWZHHQ WKH WZR WUHDWPHQW DUPV LQ WKH SURSRUWLRQ RI VWXG\ H\HV ZLWK DEVHQFH
RI DQWHULRU FKDPEHU FHOOV LH VFRUH RI µ¶ DW 9LVLW  

,I WKH SURSRUWLRQ RI VWXG\ H\HV ZLWK DEVHQFH RI DQWHULRU FKDPEHU FHOOV VFRUH RI µ¶ LV
VWDWLVWLFDOO\ VLJQLILFDQWO\ KLJKHU IRU 2&6 YHUVXV SODFHER YHKLFOH DW D VLGHG DOSKD   DW
9LVLW  
IRU 2&6 WKHQ WKH VWXG\ ZLOO EH FRQVLGHUHG D VXFFHVV DQG WKH QH[W
KLHUDUFKLFDO K\SRWKHVLV ZLOO EH WHVWHG
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 












9LVLW  ²
x
2FXODU SDLQ VWXG\ H\H RQO\
9LVLW  ²
x
0HGLFDO DQG PHGLFDWLRQV XSGDWH
x
x
3LQKROH 9$
x
6OLW ODPS ELRPLFURVFRS\
x
x
,23
x
4XHU\ IRU $(
9LVLW  ²
x
0HGLFDO DQG PHGLFDWLRQV XSGDWH
x
x
3LQKROH 9$
x
6OLW ODPS ELRPLFURVFRS\
x
x
,23
x
4XHU\ IRU $(V
9LVLW  ²
x
0HGLFDO DQG PHGLFDWLRQV XSGDWH
x
x
3LQKROH 9$
x
6OLW ODPS ELRPLFURVFRS\
x
x
,23
x
4XHU\ IRU $(V
9LVLW  ²
x
8ULQH SUHJQDQF\ WHVW LI DSSOLFDEOH
x
0HGLFDO DQG PHGLFDWLRQV XSGDWH
x
x
3LQKROH 9$
x
6OLW ODPS ELRPLFURVFRS\
x
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 







$'9(56( (9(176

$GYHUVH (YHQW
$Q $( LV GHILQHG DV DQ\ XQWRZDUG PHGLFDO RFFXUUHQFH DVVRFLDWHG ZLWK WKH XVH RI D GUXJ LQ
KXPDQV ZKHWKHU RU QRW WKH HYHQW LV FRQVLGHUHG GUXJUHODWHG $Q $( FDQ WKHUHIRUH EH DQ\
XQIDYRUDEOH DQG XQLQWHQGHG VLJQ HJ DQ DEQRUPDO ODERUDWRU\ ILQGLQJ V\PSWRP RU GLVHDVH
RFFXUULQJ DIWHU WKH VXEMHFW VWDUWHG GRVLQJ ZLWK WKH VWXG\ GUXJ ZLWKRXW DQ\ MXGJPHQW DERXW
FDXVDOLW\ $Q\ SUHH[LVWLQJ PHGLFDO FRQGLWLRQ WKDW ZRUVHQV DIWHU DGPLQLVWUDWLRQ RI WKH VWXG\ GUXJ
ZLOO DOVR EH FRQVLGHUHG D QHZ $( 6WXG\ GUXJ LQFOXGHV WKH VWXG\ GUXJ XQGHU HYDOXDWLRQ 2&6
DQG DQ\ FRPSDUDWRU GUXJ SODFHER YHKLFOH RU DQ\ RWKHU PHGLFDWLRQV UHTXLUHG E\ WKH SURWRFRO
JLYHQ GXULQJ DQ\ VWDJH RI WKH VWXG\
'RFXPHQWDWLRQ UHJDUGLQJ WKH $( VKRXOG EH PDGH DV WR WKH QDWXUH GDWH RI RQVHW HQG GDWH
VHYHULW\ UHODWLRQVKLS WR VWXG\ GUXJ DFWLRQV WDNHQ VHULRXVQHVV DQG RXWFRPH RI DQ\ VLJQ RU
V\PSWRP REVHUYHG E\ WKH SK\VLFLDQ RU UHSRUWHG E\ WKH VXEMHFW XSRQ LQGLUHFW TXHVWLRQLQJ

6HYHULW\
6HYHULW\ RI DQ $( LV GHILQHG DV D TXDOLWDWLYH DVVHVVPHQW RI WKH GHJUHH RI LQWHQVLW\ RI DQ $( DV
GHWHUPLQHG E\ WKH ,QYHVWLJDWRU RU UHSRUWHG WR KLPKHU E\ WKH VXEMHFW 7KH DVVHVVPHQW RI VHYHULW\
LV PDGH LUUHVSHFWLYH RI WKH UHODWLRQVKLS WR VWXG\ GUXJ RU WKH VHULRXVQHVV RI WKH HYHQW DQG VKRXOG
EH HYDOXDWHG DFFRUGLQJ WR WKH IROORZLQJ VFDOH
x
0LOG $( LV QRWLFHDEOH WR WKH VXEMHFW EXW LV HDVLO\ WROHUDWHG DQG GRHV QRW LQWHUIHUH ZLWK
WKH VXEMHFW¶V GDLO\ DFWLYLWLHV
x
0RGHUDWH $( LV ERWKHUVRPH SRVVLEO\ UHTXLULQJ DGGLWLRQDO WKHUDS\ DQG PD\ LQWHUIHUH
ZLWK WKH VXEMHFW¶V GDLO\ DFWLYLWLHV
x
6HYHUH $( LV LQWROHUDEOH QHFHVVLWDWHV DGGLWLRQDO WKHUDS\ RU DOWHUDWLRQ RI WKHUDS\ DQG
LQWHUIHUHV ZLWK WKH VXEMHFW¶V GDLO\ DFWLYLWLHV

5HODWLRQVKLS WR 6WXG\ 'UXJ
7KH UHODWLRQVKLS RI HDFK $( WR WKH VWXG\ GUXJ VKRXOG EH GHWHUPLQHG E\ WKH ,QYHVWLJDWRU XVLQJ
WKHVH H[SODQDWLRQV
x
6XVSHFWHG $ UHDVRQDEOH SRVVLELOLW\ H[LVWV WKDW WKH VWXG\ GUXJ FDXVHG WKH $(
x
1RW 6XVSHFWHG $ UHDVRQDEOH SRVVLELOLW\ GRHV QRW H[LVW WKDW WKH VWXG\ GUXJ FDXVHG WKH $(
³6XVSHFWHG DGYHUVH UHDFWLRQ´ PHDQV DQ\ $( IRU ZKLFK WKHUH LV D UHDVRQDEOH SRVVLELOLW\ WKDW WKH
VWXG\ GUXJ FDXVHG WKH $( ³5HDVRQDEOH SRVVLELOLW\´ PHDQV WKHUH LV HYLGHQFH WR VXJJHVW D FDXVDO
UHODWLRQVKLS EHWZHHQ WKH VWXG\ GUXJ DQG WKH $( 7\SHV RI HYLGHQFH WKDW ZRXOG VXJJHVW D FDXVDO
UHODWLRQVKLS EHWZHHQ WKH VWXG\ GUXJ DQG WKH $( LQFOXGH D VLQJOH RFFXUUHQFH RI DQ HYHQW WKDW LV
XQFRPPRQ DQG NQRZQ WR EH VWURQJO\ DVVRFLDWHG ZLWK GUXJ H[SRVXUH HJ DQJLRHGHPD KHSDWLF
LQMXU\ 6WHYHQV-RKQVRQ 6\QGURPH RQH RU PRUH RFFXUUHQFHV RI DQ HYHQW WKDW LV QRW FRPPRQO\
DVVRFLDWHG ZLWK GUXJ H[SRVXUH EXW LV RWKHUZLVH XQFRPPRQ LQ WKH SRSXODWLRQ H[SRVHG WR WKH GUXJ
HJ WHQGRQ UXSWXUH DQ DJJUHJDWH DQDO\VLV RI VSHFLILF HYHQWV REVHUYHG LQ D FOLQLFDO WULDO VXFK DV
NQRZQ FRQVHTXHQFHV RI WKH XQGHUO\LQJ GLVHDVH RU FRQGLWLRQ XQGHU LQYHVWLJDWLRQ RU RWKHU HYHQWV
WKDW FRPPRQO\ RFFXU LQ WKH VWXG\ SRSXODWLRQ LQGHSHQGHQW RI GUXJ WKHUDS\ WKDW LQGLFDWHV WKRVH
HYHQWV RFFXU PRUH IUHTXHQWO\ LQ WKH GUXJ WUHDWPHQW JURXS WKDQ LQ D FRQFXUUHQW RU KLVWRULFDO
FRQWURO JURXS
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 



([SHFWHGQHVV
7KH H[SHFWHGQHVV RI DQ $( VKRXOG EH GHWHUPLQHG EDVHG XSRQ H[LVWLQJ VDIHW\ LQIRUPDWLRQ DERXW
WKH VWXG\ GUXJ XVLQJ WKHVH H[SODQDWLRQV
x
8QH[SHFWHG DQ $( WKDW LV QRW OLVWHG LQ WKH ,QYHVWLJDWRU¶V %URFKXUH ,% RU LV QRW OLVWHG DW
WKH VSHFLILFLW\ RU VHYHULW\ WKDW KDV EHHQ REVHUYHG
x
([SHFWHG DQ $( WKDW LV OLVWHG LQ WKH ,% DW WKH VSHFLILFLW\ DQG VHYHULW\ WKDW KDV EHHQ
REVHUYHG
$(V WKDW DUH PHQWLRQHG LQ WKH ,% DV RFFXUULQJ ZLWK D FODVV RI GUXJV RU DV DQWLFLSDWHG IURP WKH
SKDUPDFRORJLFDO SURSHUWLHV RI WKH GUXJ EXW DUH QRW VSHFLILFDOO\ PHQWLRQHG DV RFFXUULQJ ZLWK WKH
SDUWLFXODU GUXJ XQGHU LQYHVWLJDWLRQ DUH WR EH FRQVLGHUHG XQH[SHFWHG
3UHOLPLQDU\ GHWHUPLQDWLRQ RI FODVVLILFDWLRQ RI DQ $( DV XQH[SHFWHG LV WKH UHVSRQVLELOLW\ RI WKH
,QYHVWLJDWRU DQG VXEMHFW WR WKH 0HGLFDO 0RQLWRU¶V ILQDO GHWHUPLQDWLRQ

6HULRXV $GYHUVH (YHQWV
$Q $( LV FRQVLGHUHG VHULRXV LI LQ WKH YLHZ RI HLWKHU WKH ,QYHVWLJDWRU RU 6SRQVRU LW UHVXOWV LQ DQ\
RI WKH IROORZLQJ RXWFRPHV
x
'HDWK
x
$ OLIHWKUHDWHQLQJ $(
1RWH $Q $( LV FRQVLGHUHG ³OLIHWKUHDWHQLQJ´ LI LQ WKH YLHZ RI HLWKHU WKH ,QYHVWLJDWRU RU
6SRQVRU LWV RFFXUUHQFH SODFHV WKH VXEMHFW DW LPPHGLDWH ULVN RI GHDWK ,W GRHV QRW LQFOXGH DQ$(
WKDW KDG LW RFFXUUHG LQ D PRUH VHYHUH IRUP PLJKW KDYH FDXVHG GHDWK
x
,QSDWLHQW KRVSLWDOL]DWLRQ RU SURORQJDWLRQ RI H[LVWLQJ KRVSLWDOL]DWLRQ
1RWH 7KH WHUP ³LQSDWLHQW KRVSLWDOL]DWLRQ´ UHIHUV WR DQ\ LQSDWLHQW DGPLVVLRQ HYHQ LI OHVV WKDQ
 KRXUV )RU FKURQLF RU ORQJWHUP LQSDWLHQWV LQSDWLHQW DGPLVVLRQ LQFOXGHV WUDQVIHU ZLWKLQ
WKH KRVSLWDO WR DQ DFXWHLQWHQVLYH FDUH LQSDWLHQW XQLW ,QSDWLHQW KRVSLWDOL]DWLRQ GRHV QRW
LQFOXGH HPHUJHQF\ URRP YLVLWV RXWSDWLHQWVDPHGD\DPEXODWRU\ SURFHGXUHV
REVHUYDWLRQVKRUW VWD\ XQLWV UHKDELOLWDWLRQ IDFLOLWLHV KRVSLFH IDFLOLWLHV QXUVLQJ KRPHV RU
FOLQLFDO UHVHDUFK3KDVH  XQLWV
1RWH 7KH WHUP ³SURORQJDWLRQ RI H[LVWLQJ KRVSLWDOL]DWLRQ´ UHIHUV WR DQ\ H[WHQVLRQ RI DQ LQSDWLHQW
KRVSLWDOL]DWLRQ EH\RQG WKH VWD\ DQWLFLSDWHG RU UHTXLUHG IRU WKH UHDVRQ IRU WKH LQLWLDO DGPLVVLRQ DV
GHWHUPLQHG E\ WKH ,QYHVWLJDWRU RU WUHDWLQJ SK\VLFLDQ
x
$ SHUVLVWHQW RU VLJQLILFDQW LQFDSDFLW\ RU VXEVWDQWLDO GLVUXSWLRQ RI WKH DELOLW\ WR FRQGXFW
QRUPDO OLIH IXQFWLRQV
1RWH $ 6$(V VSHFLILFDOO\ UHODWHG WR YLVXDO WKUHDW ZRXOG EH LQWHUSUHWHG DV DQ\ SRWHQWLDO
LPSDLUPHQW RU GDPDJH WR WKH VXEMHFW¶V H\HV HJ KHPRUUKDJH UHWLQDO GHWDFKPHQW FHQWUDO
FRUQHDO XOFHU RU GDPDJH WR WKH RSWLF QHUYH
x
$ FRQJHQLWDO DQRPDO\ELUWK GHIHFW
,PSRUWDQW PHGLFDO HYHQWV WKDW PD\ QRW UHVXOW LQ GHDWK DUH OLIHWKUHDWHQLQJ RU UHTXLUH
KRVSLWDOL]DWLRQ PD\ EH FRQVLGHUHG VHULRXV ZKHQ EDVHG XSRQ DSSURSULDWH PHGLFDO MXGJPHQW WKH\
PD\ MHRSDUGL]H WKH VXEMHFW DQG PD\ UHTXLUH PHGLFDO RU VXUJLFDO LQWHUYHQWLRQ WR SUHYHQWRQH RI WKH
RXWFRPHV OLVWHG LQ WKLV GHILQLWLRQ
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 



3URFHGXUHV IRU 5HSRUWLQJ $GYHUVH (YHQWV
$OO $(V DQG WKHLU RXWFRPHV PXVW EH UHSRUWHG WR 2UD WKH VWXG\ 6SRQVRU DQG WKH ,5% DV UHTXLUHG
E\ WKH ,5% IHGHUDO VWDWH RU ORFDO UHJXODWLRQV DQG JRYHUQLQJ KHDOWK DXWKRULWLHV DQG UHFRUGHG RQ
WKH DSSURSULDWH H&5)

5HSRUWLQJ D 6XVSHFWHG 8QH[SHFWHG $GYHUVH 5HDFWLRQ
$OO $(V WKDW DUH µVXVSHFWHG¶ DQG µXQH[SHFWHG¶ DUH WR EH UHSRUWHG WR 2UD WKH VWXG\ 6SRQVRU DQG
WKH ,5% DV UHTXLUHG E\ WKH ,5% UHJLRQDO DQG ORFDO UHJXODWLRQV DQG JRYHUQLQJ KHDOWK DXWKRULWLHV

5HSRUWLQJ D 6HULRXV $GYHUVH (YHQW
7R HQVXUH VXEMHFW VDIHW\ DOO 6$(V UHJDUGOHVV RI WKHLU UHODWLRQVKLS WR WKH VWXG\ GUXJ PXVW EH
LPPHGLDWHO\ UHSRUWHG $OO LQIRUPDWLRQ UHOHYDQW WR WKH 6$( PXVW EH UHFRUGHG RQ WKH DSSURSULDWH
FDVH UHSRUW IRUPV 7KH ,QYHVWLJDWRU LV REOLJDWHG WR SXUVXH DQG REWDLQ LQIRUPDWLRQ UHTXHVWHG E\
2UD DQGRU WKH 6SRQVRU LQ DGGLWLRQ WR WKDW LQIRUPDWLRQ UHSRUWHG RQ WKH FDVH UHSRUW IRUP $OO
VXEMHFWV H[SHULHQFLQJ DQ 6$( PXVW EH IROORZHGXS ZLWK DQG WKH RXWFRPH UHSRUWHG
,Q WKH HYHQW RI DQ 6$( WKH ,QYHVWLJDWRU PXVW QRWLI\ 2UD DQG WKH 6SRQVRU XSRQ EHFRPLQJ DZDUH
RI D 6$( REWDLQ DQG PDLQWDLQ LQ KLVKHU ILOHV LQFOXGLQJ DOO SHUWLQHQW PHGLFDO UHFRUGV
LQIRUPDWLRQ DQG PHGLFDO MXGJPHQWV IURP FROOHDJXHV ZKR DVVLVWHG LQ WKH WUHDWPHQW DQG IROORZXS
RI WKH VXEMHFW SURYLGH 2UD DQG WKH VWXG\ 6SRQVRU ZLWK D FRPSOHWH FDVH KLVWRU\ ZKLFK LQFOXGHV D
VWDWHPHQW DV WR ZKHWKHU WKH HYHQW ZDV RU ZDV QRW VXVSHFWHG WR EH UHODWHG WR WKH XVH RI WKH VWXG\
GUXJ DQG LQIRUP WKH ,5% RI WKH $( ZLWKLQ WKHLU JXLGHOLQHV IRU UHSRUWLQJ 6$(V
,QYHVWLJDWRUV DUH WR FRQWDFW WKH VWXG\¶V 0HGLFDO 0RQLWRU RU GHVLJQHH XSRQ EHFRPLQJ DZDUH RI D
6$(

3URFHGXUHV IRU 8QPDVNLQJ RI 6WXG\ 'UXJ
7KH UDQGRPL]DWLRQ FRGH VKRXOG EH EURNHQ RQO\ LQ WKH HYHQW RI D PHGLFDO HPHUJHQF\ RU ZKHQ
NQRZLQJ WKH WUHDWPHQW DVVLJQPHQW LV DEVROXWHO\ QHFHVVDU\ IRU WKH PHGLFDO PDQDJHPHQW RI WKH
VWXG\ VXEMHFW :KHQ SRVVLEOH LH LQ QRQHPHUJHQF\ VLWXDWLRQV WKH VWXG\ 6SRQVRU RU
UHSUHVHQWDWLYH VKRXOG EH QRWLILHG SULRU WR XQPDVNLQJ VWXG\ GUXJ ,Q HPHUJHQF\ VLWXDWLRQV WKH
,QYHVWLJDWRU PXVW QRWLI\ WKH 6SRQVRU ZLWKLQ  KRXUV DIWHU GHWHUPLQLQJ WKDW LW LV QHFHVVDU\ WR
XQPDVN WKH WUHDWPHQW DVVLJQPHQW 7KH ,QYHVWLJDWRU PXVW DOVR LQGLFDWH LQ VRXUFH GRFXPHQWV DQG
LQ WKH H&5) WKDW WKH PDVN ZDV EURNHQ DQG SURYLGH WKH GDWH WLPH DQG UHDVRQ IRU EUHDNLQJ WKH
PDVN $Q\ $( RU 6$( DVVRFLDWHG ZLWK EUHDNLQJ WKH PDVN PXVW EH UHFRUGHG DQG UHSRUWHG DV
VSHFLILHG LQ WKLV SURWRFRO

7\SH DQG 'XUDWLRQ RI WKH )ROORZXS RI 6XEMHFWV DIWHU $GYHUVH (YHQWV
$(V ZLOO EH IROORZHG XQWLO WKH FRQGLWLRQ LV UHVROYHG RU VWDELOL]HG
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 















3URWHFWLRQ RI +XPDQ 6XEMHFWV

6XEMHFW ,QIRUPHG &RQVHQW
,QIRUPHG FRQVHQW PXVW WDNH SODFH EHIRUH DQ\ VWXG\ VSHFLILF SURFHGXUHV DUH LQLWLDWHG 6LJQHG DQG
GDWHG ZULWWHQ LQIRUPHG FRQVHQW PXVW EH REWDLQHG IURP HDFK VXEMHFW SULRU WR HQUROOPHQW LQWR WKH
VWXG\
$OO ,&)V PXVW EH DSSURYHG IRU XVH E\ WKH 6SRQVRU DQG UHFHLYH DSSURYDOIDYRUDEOH RSLQLRQ IURP
DQ ,5% SULRU WR WKHLU XVH ,I WKH FRQVHQW IRUP UHTXLUHV UHYLVLRQ HJ GXH WR D SURWRFRO
DPHQGPHQW RU VLJQLILFDQW QHZ VDIHW\ LQIRUPDWLRQ LW LV WKH LQYHVWLJDWRU¶V UHVSRQVLELOLW\ WR HQVXUH
WKDW WKH DPHQGHG LQIRUPHG FRQVHQW LV UHYLHZHG DQG DSSURYHG E\ 2UD SULRU WR VXEPLVVLRQ WR WKH
JRYHUQLQJ ,5% DQG WKDW LW LV UHDG VLJQHG DQG GDWHG E\ DOO VXEMHFWV VXEVHTXHQWO\ HQUROOHG LQ WKH
VWXG\ DV ZHOO DV WKRVH FXUUHQWO\ HQUROOHG LQ WKH VWXG\

,QVWLWXWLRQDO 5HYLHZ %RDUG $SSURYDO
7KLV VWXG\ LV WR EH FRQGXFWHG LQ DFFRUGDQFH ZLWK ,5% UHJXODWLRQV 86  &RGH RI )HGHUDO
5HJXODWLRQV >&)5@ 3DUW  7KH ,QYHVWLJDWRU PXVW REWDLQ DSSURSULDWH ,5% DSSURYDO EHIRUH
LQLWLDWLQJ WKH VWXG\ DQG UHDSSURYDO DW OHDVW DQQXDOO\
2QO\ DQ ,5% DSSURYHG YHUVLRQ RI WKH ,&) ZLOO EH XVHG

(WKLFDO &RQGXFW RI WKH 6WXG\
7KLV VWXG\ ZLOO EH FRQGXFWHG LQ DFFRUGDQFH ZLWK WKH HWKLFDO SULQFLSOHV WKDW RULJLQDWHG ZLWK WKH
'HFODUDWLRQ RI +HOVLQNL

6XEMHFW &RQILGHQWLDOLW\
$OO SHUVRQDO VWXG\ VXEMHFW GDWD FROOHFWHG DQG SURFHVVHG IRU WKH SXUSRVHV RI WKLV VWXG\ VKRXOG EH
PDLQWDLQHG E\ WKH ,QYHVWLJDWRU DQG KLVKHU VWDII ZLWK DGHTXDWH SUHFDXWLRQV DV WR HQVXUH WKDW WKH
FRQILGHQWLDOLW\ RI WKH GDWD LQ DFFRUGDQFH ZLWK ORFDO VWDWH DQG IHGHUDO ODZV DQG UHJXODWLRQV
0RQLWRUV DXGLWRUV DQG RWKHU DXWKRUL]HG UHSUHVHQWDWLYHV RI 2UD WKH 6SRQVRU WKH ,5% DSSURYLQJ
WKLV VWXG\ WKH )'$ WKH 'HSDUWPHQW RI +HDOWK DQG +XPDQ 6HUYLFHV RWKHU GRPHVWLF JRYHUQPHQW
DJHQFLHV DQG RWKHU IRUHLJQ UHJXODWRU\ DJHQFLHV ZLOO EH JUDQWHG GLUHFW DFFHVV WR WKH VWXG\
VXEMHFW¶V RULJLQDO PHGLFDO DQG VWXG\ UHFRUGV IRU YHULILFDWLRQ RI WKH GDWD DQGRU FOLQLFDO WULDO
SURFHGXUHV $FFHVV WR WKLV LQIRUPDWLRQ ZLOO EH SHUPLWWHG WR WKH DIRUHPHQWLRQHG LQGLYLGXDOV WR WKH
H[WHQW SHUPLWWHG E\ ODZ
$ UHSRUW RI WKH UHVXOWV RI WKLV VWXG\ PD\ EH SXEOLVKHG RU VHQW WR WKH DSSURSULDWH KHDOWK DXWKRULWLHV
LQ DQ\ FRXQWU\ LQ ZKLFK WKH VWXG\ GUXJ PD\ XOWLPDWHO\ EH PDUNHWHG EXW WKH VXEMHFW¶V LGHQWLW\
ZLOO QRW EH GLVFORVHG LQ WKHVH GRFXPHQWV

'RFXPHQWDWLRQ
6RXUFH GRFXPHQWV PD\ LQFOXGH D VXEMHFW¶V PHGLFDO UHFRUGV KRVSLWDO FKDUWV FOLQLF FKDUWV WKH
,QYHVWLJDWRU¶V VWXG\ VXEMHFW ILOHV DV ZHOO DV WKH UHVXOWV RI GLDJQRVWLF WHVWV VXFK DV ;UD\V
ODERUDWRU\ WHVWV DQG HOHFWURFDUGLRJUDPV 7KH ,QYHVWLJDWRU¶V FRS\ RI WKH H&5) VHUYHV DV WKH
,QYHVWLJDWRU¶V UHFRUG RI D VXEMHFW¶V VWXG\UHODWHG GDWD
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 



5HWHQWLRQ RI 'RFXPHQWDWLRQ
$OO VWXG\ UHODWHG FRUUHVSRQGHQFH VXEMHFW UHFRUGV FRQVHQW IRUPV UHFRUG RI WKH GLVWULEXWLRQ DQG
XVH RI DOO VWXG\ GUXJ DQG FRSLHV RI FDVH UHSRUW IRUPV VKRXOG EH PDLQWDLQHG RQ ILOH IRU DW OHDVW WZR
\HDUV DIWHU WKH ODVW DSSURYDO RI D PDUNHWLQJ DSSOLFDWLRQ LQ DQ ,&+ UHJLRQ DQG XQWLO WKHUH DUH QR
SHQGLQJ RU FRQWHPSODWHG PDUNHWLQJ DSSOLFDWLRQV LQ DQ ,&+ UHJLRQ RU XQWLO DW OHDVW WZR \HDUV
KDYH HODSVHG VLQFH WKH IRUPDO GLVFRQWLQXDWLRQ RI FOLQLFDO GHYHORSPHQW RI WKH VWXG\ GUXJ 7KHVH
GRFXPHQWV ZLOO EH UHWDLQHG IRU D ORQJHU SHULRG LI UHTXLUHG E\ WKH DSSOLFDEOH UHJXODWRU\
UHTXLUHPHQWV RU E\ DQ DJUHHPHQW ZLWK WKH 6SRQVRU ,W LV WKH UHVSRQVLELOLW\ RI WKH 6SRQVRU WR
LQIRUP WKH LQYHVWLJDWRULQVWLWXWLRQ DV WR ZKHQ WKHVH GRFXPHQWV QR ORQJHU QHHG WR EH UHWDLQHG
,I WKH UHVSRQVLEOH ,QYHVWLJDWRU UHWLUHV UHORFDWHV RU IRU RWKHU UHDVRQV ZLWKGUDZV IURP WKH
UHVSRQVLELOLW\ RI NHHSLQJ VWXG\ UHFRUGV FXVWRG\ PXVW EH WUDQVIHUUHG WR D SHUVRQ ZKR ZLOO DFFHSW
WKH UHVSRQVLELOLW\ 7KH 6SRQVRU PXVW EH QRWLILHG LQ ZULWLQJ RI WKH QDPH DQG DGGUHVV RI WKH QHZ
FXVWRGLDQ

/DEHOLQJ 3DFNDJLQJ 6WRUDJH $FFRXQWDELOLW\ DQG 5HWXUQ RU 'LVSRVDO RI 6WXG\
'UXJ

/DEHOLQJ3DFNDJLQJ
6WXG\ GUXJ ZLOO EH SDFNHG LQ VLQJOHXVH YLDOV ZLWKLQ DOXPLQXP SRXFKHV ZKLFK ZLOO EH
FRQWDLQHG LQ NLWV 5HIHU WR WKH ,3 PDQXDO IRU WKH VSHFLILF QXPEHU RI YLDOV LQ SRXFKHV SRXFKHV
LQ NLWV DQG QXPEHU RI NLWV $OO VWXG\ GUXJV ZLOO EH ODEHOHG DFFRUGLQJ WR DSSOLFDEOH UHJXODWRU\
UHTXLUHPHQWV

6WRUDJH RI 6WXG\ 'UXJ
7KH VWXG\ GUXJ PXVW EH VWRUHG LQ D VHFXUH DUHD DFFHVVLEOH RQO\ WR WKH ,QYHVWLJDWRU DQG KLVKHU
GHVLJQHHV 7KH VWXG\ GUXJ ZLOO EH GLVSHQVHG RQO\ WR VXEMHFWV HQWHUHG LQWR WKH FOLQLFDO VWXG\ LQ
DFFRUGDQFH ZLWK WKH FRQGLWLRQV VSHFLILHG LQ WKLV SURWRFRO
8QGLVSHQVHG VWXG\ GUXJ VKRXOG EH VWRUHG DW URRP WHPSHUDWXUH &
2QFH GLVSHQVHG WR VXEMHFWV VWXG\ GUXJ VKRXOG EH VWRUHG DW DPELHQW WHPSHUDWXUH

$FFRXQWDELOLW\ RI 6WXG\ 'UXJ
7KH VWXG\ GUXJ LV WR RQO\ EH SUHVFULEHG E\ WKH 3, RU KLVKHU QDPHG VXE,QYHVWLJDWRUV DQG LV WR
RQO\ EH XVHG LQ DFFRUGDQFH ZLWK WKLV SURWRFRO 7KH VWXG\ GUXJ PXVW RQO\ EH GLVWULEXWHG WR
VXEMHFWV HOLJLEOH XQGHU WKLV SURWRFRO WR UHFHLYH VWXG\ GUXJ
7KH ,QYHVWLJDWRU RU KLVKHU GHVLJQHH PXVW NHHS DQ DFFXUDWH DFFRXQWLQJ RI WKH VWXG\ GUXJ UHFHLYHG
IURP WKH VXSSOLHU 7KLV LQFOXGHV WKH DPRXQW RI VWXG\ GUXJ GLVSHQVHG WR VXEMHFWV DPRXQW RI VWXG\
GUXJ UHWXUQHG WR WKH ,QYHVWLJDWRU E\ WKH VXEMHFWV DQG WKH DPRXQW UHWXUQHG RU GLVSRVHG XSRQ WKH
FRPSOHWLRQ RI WKH VWXG\ $ GHWDLOHG LQYHQWRU\ PXVW EH FRPSOHWHG IRU WKH VWXG\ GUXJ

5HWXUQ RU 'LVSRVDO RI 6WXG\ 'UXJ
$W WKH HQG RI WKH VWXG\ DOO VWXG\ GUXJV ZLOO EH UHWXUQHG WR WKH 6SRQVRU RU WKHLU GHVLJQHH RU
GHVWUR\HG DW WKH VWXG\ VLWH 7KH UHWXUQ RU GLVSRVDO RI VWXG\ GUXJ ZLOO EH VSHFLILHG LQ ZULWLQJ
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 



5HFRUGLQJ RI 'DWD RQ 6RXUFH 'RFXPHQWV DQG &DVH 5HSRUW )RUPV
$OO VXEMHFW GDWD ZLOO EH FDSWXUHG LQ WKH VXEMHFW VRXUFH GRFXPHQWV ZKLFK ZLOO EH WUDQVFULEHG LQ WKH
H&5)V 7KH ,QYHVWLJDWRU LV UHVSRQVLEOH IRU HQVXULQJ WKDW VWXG\ GDWD LV FRPSOHWHO\ DQG DFFXUDWHO\
UHFRUGHG RQ HDFK VXEMHFW¶V H&5) VRXUFH GRFXPHQWV DQG DOO VWXG\UHODWHG PDWHULDOV $OO VWXG\
GDWD VKRXOG DOVR EH DWWULEXWDEOH OHJLEOH FRQWHPSRUDQHRXV DQG RULJLQDO 5HFRUGHG GDWXP VKRXOG
RQO\ EH FRUUHFWHG LQ D PDQQHU WKDW GRHV QRW REOLWHUDWH GHVWUR\ RU UHQGHU LOOHJLEOH WKH SUHYLRXV
HQWU\ HJ E\ GUDZLQJ D VLQJOH OLQH WKURXJK WKH LQFRUUHFW HQWU\ DQG ZULWLQJ WKH UHYLVLRQ QH[W WR
WKH FRUUHFWHG GDWD $Q LQGLYLGXDO ZKR KDV FRUUHFWHG D GDWD HQWU\ VKRXOG PDNH FOHDU ZKR PDGH
WKH FRUUHFWLRQ DQG ZKHQ E\ DGGLQJ WR WKH FRUUHFWLRQ KLVKHU LQLWLDOV DV ZHOO DV WKH GDWH RI WKH
FRUUHFWLRQ
'DWD HQWU\ RI DOO HQUROOHG DQG UDQGRPL]HG VXEMHFWV ZLOO XVH VRIWZDUH WKDW FRQIRUPV WR  &)5
3DUW  UHTXLUHPHQWV DQG ZLOO EH SHUIRUPHG RQO\ E\ VWDII ZKR KDYH EHHQ WUDLQHG RQ WKH V\VWHP
DQG KDYH DFFHVV WR WKH V\VWHP $Q DXGLW WUDLO ZLOO EH PDLQWDLQHG ZLWKLQ WKH HOHFWURQLF V\VWHP WR
FDSWXUH DOO FKDQJHV PDGH ZLWKLQ WKH H&5) GDWDEDVH $IWHU WKH HQG RI WKH VWXG\ DQG GDWDEDVH
ORFN FRPSDFW GLVFV &'V FRQWDLQLQJ FRSLHV RI DOO DSSOLFDEOH VXEMHFWV¶ H&5)V ZLOO EH SURYLGHG
WR HDFK ,QYHVWLJDWRU 6LWH WR EH PDLQWDLQHG RQ ILOH E\ WKH ,QYHVWLJDWRU

+DQGOLQJ RI %LRORJLFDO 6SHFLPHQV
1RW DSSOLFDEOH

3XEOLFDWLRQV
$XWKRUVKLS DQG PDQXVFULSW FRPSRVLWLRQ ZLOO UHIOHFW MRLQW FRRSHUDWLRQ DPRQJ DOO SDUWLHV LQYROYHG
LQ WKH VWXG\ $XWKRUVKLS ZLOO EH HVWDEOLVKHG SULRU WR WKH ZULWLQJ RI WKH PDQXVFULSW 7KH VWXG\
6SRQVRU ZLOO KDYH WKH ILQDO GHFLVLRQ UHJDUGLQJ WKH PDQXVFULSW DQG SXEOLFDWLRQ
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 


5()(5(1&(6
$OFRQ /DERUDWRULHV ,  0D[LGH[   GH[DPHWKDVRQH RSKWKDOPLF VXVSHQVLRQ
&KRL 6 + DQG / %LHORU\  /DWHSKDVH UHDFWLRQ LQ RFXODU DOOHUJ\ &XUU 2SLQ $OOHUJ\
&OLQ ,PPXQRO  
&,206  ,QWHUQDWLRQDO (WKLFDO *XLGHOLQHV IRU +HDOWKUHODWHG 5HVHDUFK ,QYROYLQJ +XPDQV
*HQHYD
)RQJ 5 % ( 6LOYHUVWHLQ - + 3HDFH - , :LOOLDPV DQG - / 9LWWLWRZ  6XEPLFURQ
ORWHSUHGQRO HWDERQDWH RSKWKDOPLF JHO  IRU WKH WUHDWPHQW RI LQIODPPDWLRQ DQG SDLQ DIWHU
FDWDUDFW VXUJHU\ - &DWDUDFW 5HIUDFW 6XUJ  
-DEV ' $ 5 % 1XVVHQEODWW - 7 5RVHQEDXP DQG * 6WDQGDUGL]DWLRQ RI 8YHLWLV 1RPHQFODWXUH
:RUNLQJ  6WDQGDUGL]DWLRQ RI XYHLWLV QRPHQFODWXUH IRU UHSRUWLQJ FOLQLFDO GDWD 5HVXOWV RI
WKH )LUVW ,QWHUQDWLRQDO :RUNVKRS $P - 2SKWKDOPRO  
0F&DIIHU\ 0 DQG $ %HHEH  3DLQ FOLQLFDO PDQXDO IRU QXUVLQJ SUDFWLFH 1XUV 6WDQG 

5DMSDO 5 . 5 )RQJ DQG 7 / &RPVWRFN  /RWHSUHGQRO HWDERQDWH RSKWKDOPLF JHO 
IROORZLQJ FDWDUDFW VXUJHU\ LQWHJUDWHG DQDO\VLV RI WZR FOLQLFDO VWXGLHV $GY 7KHU  

7RPDV]HZVNL % 7 =DOHZVND 5 	 0DULDN =  (YDOXDWLRQ RI WKH HQGRWKHOLDO FHOO
GHQVLW\ DQG WKH FHQWUDO FRUQHDO WKLFNQHVV LQ SVHXGRH[IROLDWLRQ V\QGURPH DQG SVHXGRH[IROLDWLRQ
JODXFRPD -RXUQDO RI RSKWKDOPRORJ\   KWWSVGRLRUJ
:HEHU 0 / .RGMLNLDQ ) ( .UXVH = =DJRUVNL DQG & 0 $OODLUH  (IILFDF\ DQG VDIHW\
RI LQGRPHWKDFLQ  H\H GURSV FRPSDUHG ZLWK NHWRURODF  H\H GURSV LQ WKH PDQDJHPHQW RI
RFXODU LQIODPPDWLRQ DIWHU FDWDUDFW VXUJHU\ $FWD 2SKWKDOPRO  H
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 


2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 
















$33(1',;  $33529$/6
3URWRFRO 7LWOH
3URWRFRO 1XPEHU
3URWRFRO 'DWH
$ 5DQGRPL]HG 'RXEOHPDVNHG 9HKLFOHFRQWUROOHG6WXG\
(YDOXDWLQJ WKH (IILFDF\ DQG 6DIHW\ RI 2&6 H\HGURSV FRPSDUHG
WR 9HKLFOH LQ WKH 7UHDWPHQW RI ,QIODPPDWLRQ DQG 3DLQ )ROORZLQJ
&DWDUDFW 6XUJHU\
';
0D\  
7KLV FOLQLFDO VWXG\ SURWRFRO ZDV VXEMHFW WR FULWLFDO UHYLHZ DQG KDV EHHQ DSSURYHG E\ WKH 6SRQVRU
7KH IROORZLQJ SHUVRQQHO FRQWULEXWHG WR ZULWLQJ DQGRU DSSURYLQJ WKLV SURWRFRO
2FXOLV
';
2&6
9HUVLRQ 
&RQILGHQWLDO
3DJH  RI 


$33(1',;  ,19(67,*$725¶6 6,*1$785(
3URWRFRO 7LWOH
3URWRFRO 1XPEHU
3URWRFRO 'DWH
$ 5DQGRPL]HG 'RXEOHPDVNHG 9HKLFOHFRQWUROOHG6WXG\
(YDOXDWLQJ WKH (IILFDF\ DQG 6DIHW\ RI 2&6 H\HGURSV
FRPSDUHG WR 9HKLFOH LQ WKH 7UHDWPHQW RI ,QIODPPDWLRQ DQG
3DLQ )ROORZLQJ &DWDUDFW 6XUJHU\
';
0D\  
, DJUHH WR LPSOHPHQW DQG FRQGXFW WKH VWXG\ GLOLJHQWO\ DQG LQ VWULFW FRPSOLDQFH ZLWK WKH SURWRFRO
JRRG FOLQLFDO SUDFWLFHV DQG DOO DSSOLFDEOH ODZV DQG UHJXODWLRQV , DJUHH WR PDLQWDLQ DOO
LQIRUPDWLRQ VXSSOLHG E\ WKH 6SRQVRU DQG LWV DJHQWV LQ FRQILGHQFH DQG ZKHQ WKLV LQIRUPDWLRQ LV
VXEPLWWHG WR DQ ,QVWLWXWLRQDO 5HYLHZ %RDUG ,5% (WKLFDO 5HYLHZ &RPPLWWHH (5& RU DQRWKHU
JURXS LW ZLOO EH VXEPLWWHG ZLWK D GHVLJQDWLRQ WKDW WKH PDWHULDO LV FRQILGHQWLDO
, KDYH UHDG WKLV SURWRFRO LQ LWV HQWLUHW\ LQFOXGLQJ WKH DERYH VWDWHPHQW DQG , DJUHH WR DOO DVSHFWV
6LJQHG
'DWH
1DPH
7LWOH
$IILOLDWLRQ
$GGUHVV
7HOHSKRQH QXPEHU
2FXOLV
';
2&6
&RQILGHQWLDO
3DJH  RI 

SAP_001.pdf: 
STATISTICAL ANALYSIS PLAN  
A Randomized, Double-masked, Vehicle-controlled Study Evaluating 
the Efficacy and Safety of OCS-01 eyedrops compared to Vehicle in the 
Treatment of Inflammation and Pain Following Cataract Surgery 
 
 
Sponsor: 
 
Oculis Operations Sàrl 
 
 
 
EPFL Innovation Park  
Building D 
 
 
 
1015 Lausanne, Switzerland 
 
 
Protocol Number: 
DX218 
 
 
Author:  
 
 
 
 
 
 
 
 
Date:    
 
13JUL2023 
Version:  
 
1.0 
 


A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of 
OCS-01 eyedrops compared to Vehicle in the Treatment of Inflammation and Pain Following 
Cataract Surgery 
Protocol Number: 
DX218 
SAP Version: 
1.0 
SAP Date: 
13JUL2023 








1. Introduction 
The purpose of this statistical analysis plan (SAP) is to describe the planned analyses and reporting for 
protocol DX218, Version 1.0 dated 10MAY2022. 
This SAP is being written with due consideration of the recommendations outlined in the most recent 
International Conference on Harmonisation (ICH) E9 Guideline entitled Guidance for Industry: Statistical 
Principles for Clinical Trials and the most recent ICH E3 Guideline, entitled Guidance for Industry: Structure 
and Content of Clinical Study Reports. 
This SAP describes the data that will be analyzed and the subject characteristics, efficacy, and safety 
assessments that will be evaluated. This SAP provides details of the specific statistical methods that will 
be used. The statistical analysis methods presented in this document will supersede the statistical analysis 
methods described in the clinical protocol. If additional analyses are required to supplement the planned 
analyses described in this SAP, they may be completed and will be identified in the clinical study report. 
2. Study Objectives 
The primary objective of this study is to evaluate the efficacy and safety of OCS-01 QD compared to placebo 
(vehicle) in the treatment of inflammation and pain following cataract surgery. 
2.1 
Primary Efficacy Measures 
The primary efficacy measures are the following, listed in hierarchical order: 
• 
Absence of anterior chamber cells (i.e., score of “0”) at Visit 6 (
 
• 
Absence of pain (i.e., score of “0”) at Visit 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 
Safety Measures 
The primary safety measures include the following: 
• 
Change from baseline in pin-hole visual acuity (VA) (without any other correction) as measured on 
the ETDRS chart 
• 
Change from baseline of intraocular pressure (IOP) 
• 
Change in endothelial cell density assessed at Visit 8 


• 
Adverse event (AE) rates 
Additional safety measures described in the protocol include: 
• 
Slit lamp biomicroscopy parameters; 
• 
Dilated indirect ophthalmoscopy parameters; 
• 
Endothelial cell parameters, including density, %hexagonal, and %CV. 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 








4. Study Treatments 
Study eyes will be treated with either OCS-01 (dexamethasone Ophthalmic Suspension, 1.5% (15 mg/mL) 
QD  or placebo (vehicle) QD ophthalmic suspension  during the treatment period of the study. 
4.1 
Method of Assigning Subjects to Treatment Groups 
At Visit 2 
 each subject who signed an informed consent form at Visit 1 
 will be 
assigned a screening number. Screening numbers will be assigned in sequential order at each site 
beginning with 001 and will follow the two-digit site number (e.g., subject 077 at Site 99 will have Screening 
Number 99-077). No subjects should be rescreened except in special circumstances in which sites should 
obtain approval to re-screen. Inclusion and exclusion criteria will be reviewed, and qualifying subjects will 
be enrolled into the study. Each subject who qualifies for entry will be assigned a randomization number 
and corresponding treatment according to the randomization code. Subjects will be randomly assigned to 
either OCS-01 QD or placebo (vehicle) QD using a 1:1 assignment ratio, stratified by site, via an interactive 
response system. 
Randomization numbers will be assigned in sequential order at each site beginning with 1001 and will follow 
the two digit site number (e.g., randomized subject 1005 at Site 99 will have Randomization Number 99-
1005). Sequentially numbered study drug kits will be provided to each investigational site, in accordance 
with the site-specific randomized study drug kit list, which consists of sequential 4-digit kit ID numbers. The 
interactive response system (IRT) will be utilized to assign the randomized subject the lowest 4-digit study 
drug kit number available at their investigative site associated with randomized treatment, in a masked 
manner to the site study team. If a randomized subject is discontinued from the study for any reason, their 
randomization number and randomized study drug kit number will not be reassigned.  
The subject number will be used to identify subjects in all datasets and listings for this study.  
4.2 
Masking and Unmasking 
An independent, unmasked biostatistician who is not otherwise involved in the trial will generate the 
complete randomized study drug kit list. The subject, Sponsor, Investigators, and study staff will be masked 
during the randomization process and throughout the study. 
The randomization code should be broken only in the event of a medical emergency, or when knowing the 
treatment assignment is absolutely necessary for the medical management of the study subject. When 
possible (i.e., in non-emergency situations), the study Sponsor or representative should be notified prior to 
unmasking study drug. In emergency situations, the Investigator must notify the Sponsor within 24 hours 
after determining that it is necessary to unmask the treatment assignment. The Investigator must also 
indicate in source documents and in the eCRF that the mask was broken and provide the date, time, and 
reason for breaking the mask. Any AE or SAE associated with breaking the mask must be recorded and 
reported as specified in the protocol. More details about the emergency unmasking process can be found 
in the IRT Plan as a separate document. 


 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
6. Data Preparation 
6.1 
Input Data 
Study data from source documents will be entered into the electronic Case Report Forms (eCRF) supplied 
by Statistics & Data Corporation (SDC) using the electronic data capture (EDC) system iMedNet™ v1.221.2 
or higher. Additional details about the EDC system can be found in the Data Management Plan as a 
separate document. 


In addition, the following study data which is not captured directly within the iMedNet system but is obtained 
from external vendors will also be included for analysis. These data sources are described in detail in data 
transfer agreements developed between data management and the respective external laboratory or 
reading center: 
• 
Endothelial cell density 
After data are entered into the clinical study database, electronic edit checks and data review will be 
performed. All data validation specifications and procedures are detailed in the Data Validation Manual as 
a separate document. When the database has been declared to be complete and accurate and all 
prerequisites for database lock have been met, including availability of all external data, the database will 
be locked. Following database lock, approval will be obtained from the Sponsor to unmask the study.  
Final analysis will be carried out after the following have occurred: 
• 
Database lock has occurred, including receipt of all final versions of external vendor data, with 
written authorization provided by appropriate SDC and Sponsor personnel. 
• 
Protocol deviations have been classified (major/minor deviations). 
• 
Analysis populations have been determined. 
• 
Randomized treatment codes have been unmasked. 
Any changes to the database after data have been locked or after unmasking can only be made with the 
approval of the Sponsor in consultation with SDC and per SDC standard operating procedures (SOPs). 
Adjustments to or repeats of analyses will be conducted as appropriate and in consultation with Sponsor.   
6.2 
Output Data 
Data from iMedNet and external data will be transferred to Biostatistics and incorporated into standard 
formats following the Study Data Tabulation Model (SDTM). Data will then be mapped to analysis datasets 
using the Analysis Data Model (ADaM). Both SDTM and ADaM-formatted data will be used to create the 
subject listings, while all tables and figures will be based on the ADaM-formatted data. 
SDTM will follow the SDTM version 1.7 model and will be implemented using the SDTM Implementation 
Guide version 3.3 and the most recent version of SDTM Controlled Terminology at the time of programming 
start. ADaM data will follow the ADaM version 2.1 model and will be implemented using the ADaM 
Implementation Guide version 1.1. Both SDTM and ADaM will be validated using Pinnacle 21 version 4.02. 
Any discrepancies in the validation will be noted in reviewer’s guides accompanying the final data transfers. 
Define.xml will be created for SDTM and ADaM using the Define-XML version 2.0 model. 
7. Analysis Populations 
7.1 
Full Analysis Set 
The full analysis set (FAS) will consist of all randomized subjects, analyzing subjects under the treatment 
to which they were randomized. 


7.2 
Per Protocol 
The per protocol (PP) population is a subset of the FAS and includes subjects who remain in the study 
through Visit 6 
) with no major protocol violations that would affect the assessment of the primary 
efficacy endpoints of the study, analyzing subjects under the treatment received. Major protocol violations 
will be identified prior to unmasking treatment. 
7.3 
Safety 
The safety population includes all randomized subjects who receive at least 1 dose of study medication. 
The safety population will be analyzed as treated and will be used for the safety analyses. No data will be 
excluded for any reason. 
8. General Statistical Considerations 
8.1 
Unit of Analysis 
The unit of analysis in this study will be the study eye for all ocular efficacy and safety summaries and the 
subject for all non-ocular summaries. 
8.2 
Missing or Inconclusive Data Handling 
Partial/missing start and end dates for AEs and concomitant medications will be imputed as follows: 
Partial/missing start date:  
• 
Dates with missing day only will be imputed as the 1st of the month unless the month and year are 
same as the month and year of first dose of study medication, in which case missing day will be 
imputed as the first dose day of study medication.  
• 
Dates with both day and month missing will be imputed as 1 Jan unless the year is same as the 
year of first dose of study medication, in which case missing day and month will be imputed as the 
first dose day and month of study medication. 
• 
Completely missing dates will be imputed as the first dose date of study medication unless the end 
date is on or before the first dose date of study medication, in which case missing date will be 
imputed as 1 Jan of the same year as the end date. 
Partial/missing end date:  
• 
Dates with missing day only will be imputed as the last day of the month unless the month and year 
are the same as the month and year of the last dose of study medication, in which case missing 
day will be imputed as the last dose day of study medication.  
• 
Dates with both day and month missing will be imputed as 31 Dec unless the year is same as the 
year of the last dose of study medication, in which case missing day and month will be imputed as 
the last dose day and month of study medication.  


• 
If the ongoing flag is missing or “Yes” then the date will not be imputed unless death date is 
available, in which case the missing date will be imputed as the death date. If ongoing is “No” then 
the missing end date will be imputed as the last dose date. 
• 
If the imputed date is after the date of death, then the end date will be set equal to the date of 
death.  
The original dates will be displayed in data listings and the imputed dates will be used in derivations only 
(study day, treatment-emergence status, etc.). 
The strategy for handling intercurrent events from Section 2.5 will be utilized for imputing missing data 
during the primary analyses of the primary efficacy variables. 
8.3 
Definition of Baseline 
Baseline is defined as the last measurement prior to the first dose of study medication. Change from 
baseline will be calculated as, Follow-up Visit – Baseline Visit. 
8.4 
Data Analysis Conventions 
All data analyses will be performed by SDC after the study is completed and the database has been locked 
and released for unmasking, as described in Section 6.2. Statistical programming and analyses will be 
performed using SAS® Version 9.4 or higher. Output will be provided in rich text format (RTF) for tables and 
portable document format (PDF) for tables, listings, and figures using landscape orientation. 
Summaries for continuous and ordinal variables will include the number of observations (n), arithmetic 
mean, standard deviation (SD), median, minimum, and maximum. Minima and maxima will be reported with 
the same precision as the raw values; means and medians will be presented to one additional decimal 
place than reported in the raw values. Standard deviations will be presented to two additional decimal 
places than reported in the raw values.  
Summaries for discrete variables will include counts and percentages. All percentages will be rounded to 
one decimal place (i.e., XX.X%). Differences between active treatment groups and placebo (vehicle) will 
be calculated as active minus placebo (vehicle) and change from baseline will be calculated as follow-up 
visit minus baseline.  
All statistical tests will be two-sided with a significance level of 0.05 (α = 0.05) unless otherwise specified. 
Confidence intervals (CI) for differences between treatment groups will be two-sided at 95% confidence. 
All p-values will be rounded to 4 decimal places; p-values less than 0.0001 will be presented as “<0.0001”; 
p-values greater than 0.9999 will be presented as “>0.9999.” 
Unless otherwise specified, tabular summaries will be presented by treatment group and, where 
appropriate, visit. Listings will be based on all randomized subjects, unless specified otherwise, and sorted 
by subject number, visit, and parameter as applicable. 


 
 
 
 
 
  
9. Disposition of Subjects 
Subject disposition will be presented in terms of the numbers of subjects who were screened, screen 
failures, and randomized, by treatment group and overall for all screened subjects. The numbers and 
percentages of subjects who were included in the FAS, Per-Protocol, and Safety analysis populations as 
well as who completed the study and discontinued from the study will be presented by treatment group and 
overall for all randomized subjects. Subjects who are not discontinued from the study will be considered 
study completers. The reasons for discontinuation will be summarized by treatment group and overall for 
all discontinued subjects. Percentages will be calculated using discontinued subjects as the denominator. 
The reasons for study discontinuation that will be summarized include: adverse event (AE), lost to follow-
up, protocol violation, study terminated by sponsor, withdrawal by subject, lack of efficacy, and other. The 
number and percentage of subjects with any deviation, major deviation, and minor deviation will be 
summarized by treatment group and overall for all randomized subjects. 
The reasons for screen failure (i.e., subject did not meet eligibility criteria) will be displayed with the 
percentages calculated using total number of screen failures as the denominator. 
Details of the study randomization, including study site, randomization date, randomized treatment, and 
actual treatment, will be provided within a subject listing. 
A subject listing for subject disposition will include study completion or discontinuation date, study 
completion status, and the primary reason for study discontinuation (if applicable). 
For protocol deviations, a subject listing will be provided that includes the date of the deviation, visit at which 
the deviation occurred, the deviation category, the deviation description, if the deviation was related to 
COVID-19, and the classification of whether the deviation was judged to be major or minor in a masked 
review prior to database lock. 
A subject listing of inclusion/exclusion criteria will include whether if all eligibility criteria were met, the 
specific eligibility criterion which was not met (if applicable), and the visit at which the eligibility criterion was 
not met (if applicable). 
A subject listing of analysis population inclusion will include whether criteria were met for inclusion in the 
FAS, Per-Protocol population, and Safety population. 


10. Demographic and Pretreatment Variables 
10.1 
Demographic Variables 
The demographic variables collected in this study include age, gender, ethnicity, race, and iris color. 
Subjects who record more than one race will be grouped into a single category denoted as multi-racial. Iris 
color will be summarized at the eye level. Demographic variables will be summarized for the FAS. 
Age (years) will be summarized, overall and by treatment, using continuous descriptive statistics. Age will 
also be categorized as follows: < 65 years and ≥ 65 years.   
The number and percentage of subjects will be presented, overall and by treatment, for age category, 
gender, ethnicity, race, iris color, and study site. 
A subject listing that includes all demographic variables will be provided. 
11. Medical History and Concomitant Medications 
11.1 
Medical History 
Medical history will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) Version 25.0. 
Ocular medical history will be summarized using discrete summary statistics and presented by treatment 
group and overall separately for study eyes and fellow eyes by System Organ Class (SOC) and Preferred 
Term (PT) using the Safety population. Non-ocular medical history will be similarly summarized at the 
subject level. If a subject reports the same PT multiple times within the same SOC, that PT will only be 
reported once within that SOC. As with the PT, if a subject reports multiple conditions within the same SOC, 
that SOC will only be reported once. In the summaries, SOCs will be sorted in alphabetical order, and PTs 
within an SOC will be sorted in order of descending frequency across all subjects. 
Listings of medical history will be generated separately for ocular and non-ocular data. 
11.2 
Concomitant Medications 
Concomitant medications will be coded using World Health Organization Drug Dictionary (WHODrug) 
Global B3 01Mar2022 and summarized to the therapeutic drug class (Anatomical Therapeutic Chemical 
[ATC] 4 classification) and preferred name. If the ATC 4 classification is not provided, then the next highest 
classification that is provided in the coding dictionary will be used. The preferred name will be defined as 
the active ingredient; if the active ingredient is not provided or includes more than two ingredients (e.g., 
multivitamins), then the drug name will be summarized as the preferred name.  
Prior medications are defined as those medications with an end date before the date of initiation of study 
drug administration. Concomitant medications are defined as those medications listed as having been taken 
(1) prior to initiation of study drug administration and continuing for any period of time following the first 
administration of study drug or (2) at any time following the first administration of study drug.  
Concomitant medications will be summarized using the FAS. Medications will be tabulated for each 
treatment group using frequencies and percentages. Subjects may have more than one medication per 


ATC text. At each level of subject summarization, a subject will be counted once if they report one or more 
medications. Percentages will be based on the number of subjects in each treatment group. In the 
summaries, ATC classes and preferred names within an ATC class will be sorted in alphabetical order. 
All medications utilized for lowering IOP or for rescue will be noted in the subject listing of prior and 
concomitant medications. IOP-lowering medications and rescue medications are each a subset of 
medications where the investigator has indicated on the eCRF that the medication was used to lower IOP 
or rescue. Rescue medications and criteria are described in Section 4.3. 
The number and percentage of subjects initiating IOP-lowering medications will be presented by treatment 
group for each post-baseline visit as well as across all post-baseline visits for the Safety population. 
Listings of prior and concomitant medications will be generated separately for ocular and non-ocular data. 
A separate listing will be generated for IOP-lowering medications. 
11.3 
IOP-Lowering Procedures 
All IOP-lowering procedures will be coded using MedDRA Version 25.0 and presented in a subject listing.  
12. Dosing Compliance and Treatment Exposure 
12.1 
Dosing Compliance 
Details of individual administrations of study medication done at home by subjects are not captured within 
the clinical database, therefore dosing compliance will not be summarized. 
12.2 
Treatment Exposure 
The number and percent of subjects receiving at least one dose of study medication (i.e., Safety population) 
will be summarized as part of subject disposition. 
Although not captured directly on the eCRF, additional variables related to study drug administration will 
also be derived for summarization: 
• 
Study drug interruption (yes/no), where interruptions will be identified via presence of a TEAE 
where action taken with study drug was marked as “drug interrupted” or a protocol deviation 
indicating study drug was interrupted. 
• 
Premature discontinuation of study drug (yes/no), where discontinuations will be identified via 
presence of a TEAE where action taken with study drug was marked as “drug withdrawn” or a 
protocol deviation indicating study drug was prematurely discontinued. Subjects who discontinue 
the study prior to Visit 6 (
) will also be reviewed to verify if study drug was prematurely 
discontinued or not. 
• 
Study drug completion, defined as those subjects where premature discontinuation of study drug 
is not equal to “yes”. 
A masked data review will be conducted prior to database lock and unmasking to identify any other cases 
of study drug interruption or premature discontinuation of study drug which are known to have occurred, 


but are not identified through the criteria above. The classifications from this final review will be used for 
analysis. 
The number and percentage of subjects with study drug interruption, premature discontinuation of study 
drug, and study drug completion will be presented by treatment group. 
Subject data listings will be generated to present details of study drug assignment, study drug replacement, 
as well as first instillation of study medication performed in-clinic on Visit 2 
 Details about study drug 
accountability will also be listed. 
13. Efficacy Analyses 
13.1 
Primary Analysis 
The primary efficacy variables are the following: 
• 
Absence of anterior chamber cells, defined as a score of “0,” at Visit 6 (
 
• 
Absence of pain, defined as a score of “0,” at Visit 4 (
 
The anterior chamber cell score for study eyes will be recorded as well as the anterior chamber cell count 
if the actual number of cells observed is 10 cells or fewer (only white blood cells should be counted; red 
blood cells and pigment cells should not be counted). The assessment of anterior chamber cells will be 
performed prior to any other procedure that requires dilation of the pupil, such as dilated indirect 
ophthalmoscopy, to avoid cells from being introduced into the anterior chamber. The 5-unit grading scale 
for anterior chamber cells is from 0 to 4 where 0 = 0 cells, 1 = 1 to 10 cells, 2 = 11 to 25 cells, 3 = 26 to 50 
cells, and 4 = >50 cells. Anterior chamber cell status will be classified as “Absent” for a grade of ‘0’ or 
“Present” for a grade of 1 to 4. 
Ocular pain in study eyes will be assessed by the subject utilizing a pain rating number scale graded from 
0 to 10. Subjects will assess the level of pain they are experiencing in the study eye at the time of the 
assessment. The examiner will ask the subject the following question in reference to the below figure and 
will record the number selected by the subject on the appropriate eCRF: 
On a scale of 0 to 10, in which 0 is no pain and 10 is the worst possible or unbearable pain, please mark 
on the scale the number that best describes the pain or discomfort you are feeling in the operated eye at 
this time. The middle of the scale (around 5) can be used to describe “moderate pain”. Only whole number 
scores are allowed. 








 
 
13.1.3 SENSITIVITY ANALYSIS III 
The primary efficacy analysis will be performed using the PP population with observed data only. Treatment 
comparisons will be made using Pearson’s chi-squared test. If any of the expected cell counts are less than 
five, an exact 95% CI for the difference in proportions and Fisher’s exact test will be used instead. 
13.1.4 SENSITIVITY ANALYSIS IV 
The primary efficacy analysis will be performed using the FAS with observed data only. Treatment 
comparisons will be made using Pearson’s chi-squared test. If any of the expected cell counts are less than 
five, an exact 95% CI for the difference in proportions and Fisher’s exact test will be used instead. 
13.1.5 SENSITIVITY ANALYSIS V 
The handling of intercurrent events will be updated as follows: 
• 
Receipt of rescue medication: observed data for visits after receipt of rescue medication will be 
singly imputed as failure [hypothetical strategy]. 
• 
Missing data for any reason: missing data will be singly imputed as failure [hypothetical strategy]. 
Treatment comparisons will be made using Pearson’s chi-squared test. If any of the expected cell counts 
are less than five, an exact 95% CI for the difference in proportions and Fisher’s exact test will be used 
instead. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
14. Safety Analyses 
All safety analyses will be conducted using the Safety population. 
14.1 
Adverse Events 
An Adverse Event (AE) is defined as any untoward medical occurrence associated with the use of a drug 
in humans, whether or not the event is considered drug-related. An AE can therefore be any unfavorable 
and unintended sign (e.g. an abnormal laboratory finding), symptom, or disease occurring after the subject 
started dosing with the study drug, without any judgment about causality. Any pre-existing medical condition 
that worsens after administration of the study drug will also be considered a new AE. Study drug includes 
the study drug under evaluation (OCS-01) and any comparator drug, placebo (vehicle), or any other 
medications required by the protocol given during any stage of the study. All AEs will be coded using 
MedDRA Version 25.0. 
Treatment-emergent adverse events (TEAEs) are defined as any event that occurs or worsens on or after 
the day that randomized study treatment is initiated. 
Severity of an AE is defined as a qualitative assessment of the degree of intensity of an AE as determined 
by the Investigator or reported to them by the subject. The assessment of severity is made irrespective of 
the relationship to study drug or the seriousness of the event and should be evaluated according to the 
following scale: 
• 
Mild: AE is noticeable to the subject but is easily tolerated and does not interfere with the subject’s 
daily activities. 
• 
Moderate: AE is bothersome, possibly requiring additional therapy, and may interfere with the 
subject’s daily activities. 
• 
Severe: AE is intolerable, necessitates additional therapy or alteration of therapy, and interferes 
with the subject’s daily activities. 
The relationship of each AE to the study drug should be determined by the Investigator using these 
explanations: 
• 
Suspected: A reasonable possibility exists that the study drug caused the AE. 


• 
Not Suspected: A reasonable possibility does not exist that the study drug caused the AE. 
Only suspected TEAEs are considered treatment-related TEAEs. 
The expectedness of an AE should be determined based upon existing safety information about the study 
drug using these explanations: 
• 
Unexpected: an AE that is not listed in the Investigator’s Brochure (IB) or is not listed at the 
specificity or severity that has been observed. 
• 
Expected: an AE that is listed in the IB at the specificity and severity that has been observed. 
An AE is considered serious if, in the view of either the Investigator or Sponsor, it results in any of the 
following outcomes: 
• 
Death 
• 
A life-threatening AE 
• 
Inpatient hospitalization or prolongation of existing hospitalization 
• 
A persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions 
• 
A congenital anomaly/birth defect 
TEAEs with a missing relationship to study drug will be counted as suspected treatment-related TEAEs for 
all summaries of suspected treatment-related TEAEs. All summaries of expected and unexpected TEAEs 
will include only suspected treatment-related TEAEs. TEAEs with missing severities will be counted as 
severe for all summaries by maximum severity. 
An overall summary will be presented that includes the number of events and the number and percentage 
of subjects who experienced at least one TEAE by treatment group. This summary will also include 
breakdowns of TEAEs further categorized as treatment-emergent serious adverse events (TE-SAEs), 
suspected treatment-related TEAEs, expected TEAEs, unexpected TEAEs, TEAEs leading to study drug 
discontinuation, TEAEs leading to death, and TEAEs by maximum severity. Separate summaries will be 
created for all events, ocular events in study eyes, ocular events in fellow eyes, and non-ocular events.  
TEAEs will be summarized using discrete summary statistics and presented by treatment group at the 
subject and event level by SOC and PT for the following categories of TEAEs:  
• 
Ocular TEAEs by SOC and PT 
• 
Non-Ocular TEAEs by SOC and PT 
• 
Ocular TE-SAEs by SOC and PT 
• 
Non-Ocular TE-SAEs by SOC and PT 
• 
Suspected Treatment-related Ocular TEAEs by SOC and PT 
• 
Suspected Treatment-related Non-Ocular TEAEs by SOC and PT 
• 
Expected Ocular TEAEs by SOC and PT 


• 
Expected Non-Ocular TEAEs by SOC and PT 
• 
Unexpected Ocular TEAEs by SOC and PT 
• 
Unexpected Non-Ocular TEAEs by SOC and PT 
• 
Ocular TEAEs by SOC, PT, and Maximum Severity 
• 
Non-Ocular TEAEs by SOC, PT, and Maximum Severity 
Ocular TEAEs will be summarized at the subject level for study and fellow eyes separately. If a subject 
reports the same PT multiple times within the same SOC, that PT will only be reported once within that 
SOC. As with the PT, if a subject reports multiple conditions within the same SOC, that SOC will only be 
reported once. To count the number of subjects with any TEAEs by maximum severity, if a subject has 
multiple TEAEs coded to the same SOC or PT within an SOC, the subject will be counted once under the 
maximum severity for that SOC or PT. In the summary, SOCs will be listed in ascending alphabetical order,. 
and PTs within each SOC will be listed in order of descending frequency for the OCS-01 treatment group.   
All AEs will be presented in a subject listing. In addition, all SAEs and AEs leading to study drug 
discontinuation will be presented in separate listings. 
14.2 
Pin-Hole Visual Acuity 
Pin-hole visual acuity (VA) is assessed at each visit using an Early Treatment Diabetic Retinography Study 
(ETDRS) chart. Pin-hole VA testing will be done with a pin-hole occluder at a viewing distance of 4 meters 
at the beginning of each study visit (i.e., prior to slit lamp examination). If less than 20 letters are read at 4 
meters the subject will perform the assessment again at a viewing distance of 1 meter. If at least 20 letters 
are read correctly at 4 meters, pin-hole VA is computed as 30 plus the number of letters correct at 4 meters. 
If less than 20 letters are read correctly at 4 meters, pin-hole VA is computed as the number of letters 
correct at 4 meters plus the number of letters correct at 1 meter. 
For presentations in tables and listings, pin-hole VA will be converted from number of letters correct to a 
logarithm of the minimum angle of resolution (logMAR) score using the following formula: 
logMAR VA = 1.70 – 0.02*(Number of letters correct) 
Summaries of pin-hole VA will be based on study eyes. 
Pin-hole VA actual values at Visits 1, 2, 4, 5, 6, and 7 (
 and change from 
baseline at Visits 4, 5, 6, and 7 (
) will be summarized by visit and treatment group 
using continuous summary statistics. 
Worsening of pin-hole visual acuity by at least 2 lines (10 letters) from the ETDRS scale from the previous 
visit at Visits 4, 5, 6, and 7 (
) will be summarized by visit and treatment group using 
discrete summary statistics. 
A subject listing of pinhole visual acuity by visit will be presented. 


14.3 
Intraocular Pressure (IOP) 
Intraocular pressure (IOP) in mmHg will be measured using a Goldmann application tonometer. Both eyes 
will be tested, with the right eye preceding the left eye. Two IOP measurements will initially be collected per 
eye. If the two IOP measurements differ by 2 mmHg or less, the mean of the two IOP measurements will 
be calculated and recorded as the final IOP measurement. If the two IOP measurements differ by more 
than 2 mmHg, a third (consecutive) IOP measurement will be collected and the median IOP measurement 
will be recorded as the final IOP measurement. For a given subject for a given eye, the dataset will have 
either the mean or median of the IOP measurements, but not both. The available measure will be used as 
the analysis value for IOP listings, summaries, and analyses. 
Summaries of IOP will be based on study eyes. 
IOP actual values at Visits 1, 4, 5, 6, and 7 (
) and change from baseline at 
Visits 4, 5, 6, and 7 (
) will be summarized by visit and treatment group using continuous 
summary statistics. 
Eyes with IOP of 30 mmHg or more at Visits 1, 4, 5, 6, and 7 (
) as well as 
eyes with an increase from baseline in IOP of 10 mmHg or more at Visits 4, 5, 6, and 7 (D
 
) will be summarized by visit and treatment group using discrete summary statistics. 
A subject listing of IOP by visit will be presented. 
14.4 
Endothelial Cell Parameters 
Endothelial cell density will be assessed by specular microscopy. The image of the corneal endothelium 
will be obtained when the instrument captures the light reflected from the optical interface between the 
corneal endothelium and the aqueous humor. Multiple microphotographs will be performed for each eye, 
after which the device will perform an automatic analysis of the selected area and calculate the average 
number of cells per 1 mm2. The microscope will then provide a histogram determining the endothelial cell 
population size and specify the minimum, maximum, and average cell size of the selected area. The 
pleomorphism of endothelial cells will also be evaluated, indicating the percentage of hexagonality. 
Summaries of endothelial cell parameters will be based on study eyes. 
Endothelial cell parameters (density, %hexagonal, and %CV) actual values at Visits 1 and 8 (
 and change from baseline at Visit 8 
 will be summarized by visit and treatment group 
using continuous summary statistics. The p-values from two-sample t-tests comparing changes from 
baseline in endothelial cell density parameters between treatment groups will also be presented. 
A subject listing of endothelial cell parameters by visit will be presented. 


14.5 
Dilated Indirect Ophthalmoscopy 
A dilated indirect ophthalmoscopic examination of the vitreous, retina, macula, choroid, optic nerve, and 
lens will be performed at Visits 1 and 7 (
). The results for each region will be graded 
as normal, abnormal not clinically significant (NCS), and abnormal clinically significant (CS). 
Summaries of dilated ophthalmoscopy parameters will be based on study eyes. 
The results for each region at Visits 1 and 7 (
) will be summarized by visit and 
treatment group using discrete summary statistics. Percentages will be based on the number of subjects in 
each treatment group with responses. 
Shifts from baseline at Visit 7 (
 for the dilated ophthalmoscopy parameters will be summarized by 
treatment group using discrete summary statistics. Percentages will be based on the number of subjects in 
each treatment group with responses at both Visits 1 and 7 (
 
A subject listing of the dilated ophthalmoscopy parameters will also be produced. 
14.6 
Slit-Lamp Biomicroscopy Examination 
A slit-lamp biomicroscopy examination of the eyelid, conjunctiva, cornea, anterior chamber, iris, and lens 
will be performed at each visit. The results will be graded as normal, abnormal NCS, or abnormal CS. 
Summaries of slit-lamp biomicroscopy parameters will be based on study eyes. 
The results for each region at Visits 1, 4, 5, 6, and 7 (
) will be summarized 
by visit and treatment group using discrete summary statistics. Percentages will be based on the number 
of subjects in each treatment group with responses. 
Shifts from baseline at Visits 4, 5, 6, and 7 (
) for the dilated ophthalmoscopy 
parameters will be summarized by visit and treatment group using discrete summary statistics. Percentages 
for each visit will be based on the number of subjects in each treatment group with responses at both Visit 
1 and the respective visit. 
A subject listing of the slit-lamp biomicroscopy parameters will also be produced. 
14.7 
Clinical Laboratory Data 
Results from the urine pregnancy test at Visits 1 and 7 
) will be provided in a subject 
listing. 
15. Interim Analyses 
Interim analyses will not be performed for this study. 
16. Changes from Protocol-Stated Analyses 
The SAP includes the following changes from the protocol-stated analyses: 








Listing 
16.2.4.3.3 
Prior and Concomitant IOP Lowering Medications 
All Randomized 
Subjects 
Listing 16.2.4.4 
IOP Lowering Procedures 
All Randomized 
Subjects 
Listing 16.2.4.5 
Cataract Surgery 
All Randomized 
Subjects 
Listing 16.2.5.1 
Study Drug Administration 
All Randomized 
Subjects 
Listing 16.2.5.2 
Study Drug Accountability 
All Randomized 
Subjects 
Listing 16.2.6.1 
Anterior Chamber Cells and Flare 
All Randomized 
Subjects 
Listing 16.2.6.2 
Ocular Pain 
All Randomized 
Subjects 
Listing 16.2.7.1 
Adverse Events 
All Randomized 
Subjects 
Listing 16.2.7.2 
Serious Adverse Events 
All Randomized 
Subjects 
Listing 16.2.7.3 
Adverse Events Leading to Study Drug Discontinuation 
All Randomized 
Subjects 
Listing 16.2.8 
Urine Pregnancy Test - Subjects of Childbearing Potential  
Subjects of 
Childbearing Potential 
Listing 16.2.9.1 
Pin-Hole Visual Acuity 
All Randomized 
Subjects 
Listing 16.2.9.2 
Intraocular Pressure 
All Randomized 
Subjects 
Listing 16.2.9.3 
Endothelial Cell Density 
All Randomized 
Subjects 
Listing 16.2.9.4 
Dilated Indirect Ophthalmoscopy 
All Randomized 
Subjects 
Listing 16.2.9.5 
Slit Lamp Biomicroscopy 
All Randomized 
Subjects